Idiopathic Pulmonary Fibrosis
Conditions
Brief summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Interventions
DRUGBBT-877
BBT-877 24 weeks + Follow-up 4 weeks
DRUGPlacebo
Placebo 24 weeks + Follow-up 4 weeks
Sponsors
Bridge Biotherapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male patients who have completed family planning or female patient, aged 40 years or older * Diagnosis of IPF in accordance with American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines for diagnosis in effect at the time of screening * Chest high-resolution computed tomography (HRCT) performed according to ATS guidelines within 12 months prior to screening and according to minimum requirements for IPF diagnosis by central review based on HRCT and lung biopsy. If no historical acceptable HRCT is available prior to screening, an HRCT can be performed during screening. In both cases, a central reading of the HRCT has to be done as well as a review of lung biopsy slides, if available and potentially supportive for diagnosis. * Able to walk at least 150 meters during the 6MWT at screening * Resting oxygen saturation of ≥89% using a maximum of 6 L/min of supplemental oxygen at sea level, and up to 8 L/min at altitude during screening * FVC ≥45% predicted of normal * Ratio of forced expiratory volume in the first second (FEV1) to FVC ≥0.7 * Diffusing capacity for the DLCO corrected for hemoglobin ≥30% predicted of normal * Absence of IPF improvement in the past year, as determined by the investigator * Patients receiving either pirfenidone or nintedanib, should be on it for at least 3 months and with a stable dose in the 4 weeks prior to screening, OR taking neither pirfenidone
Exclusion criteria
* Unable to perform spirometry as per ATS * Evidence of IPF exacerbation within 3 months prior to and/or during screening * Evidence of emphysema extent greater than the extent of fibrosis * Current smoker (tobacco, e-cigarette) * History of lung transplant or lung volume reduction surgery * Current immunosuppressive condition * Estimated life expectancy of less than 12 months or 30 months in the opinion of the investigator * Congestive heart failure class III or IV according to New-York Heart Association classification * Pulmonary hypertension (PH) requiring PH specific therapy * Unstable cardiovascular, pulmonary or other disease within 6 months prior to screening or during the screening period * Use of other medications likely to interfere with study assessments * Any other current or prior medical condition, medical or surgical therapies, or clinical trial participation expected to interfere with the conduct of the study or the evaluation of its results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| In patients with IPF by measuring the reduction in forced vital capacity (FVC) in mL decline compared to placebo | After 24 weeks of treatment | Change from baseline in FVC (in mL). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the effect of on diffusing capacity of lung for carbon monoxide (DLCO) of BBT-877 compared to placebo | After 24 weeks of treatment | Change from baseline compared to placebo in DLCO |
| To evaluate the effect on functional exercise capacity (measured by the 6-Minute Walk Test [6MWT]) of BBT-877 compared to placebo | After 24 weeks of treatment | Change from baseline in functional exercise capacity as measured by change in 6-minute walk distance assessed by the 6MWT |
| To assess the change in IPF impacts from the patient perspective after 24 weeks of treatment of BBT-877 compared to placebo | after 24 weeks of treatment | Change in overall respiratory health as measured by the St. George's Hospital Respiratory Questionnaire (SGRQ) total score from baseline and Change in overall IPF impacts as measured by the L-IPF total score from baseline |
| In patients with IPF by measuring the reduction in forced vital capacity (FVC) % predicted decline compared to placebo | After 24 weeks of treatment | Change from baseline in FVC (%). |
| To evaluate potential effect of BBT-877 on pharmacokinetics (PK)of each antifibrotic(AF)in patients with IPF | 0, 4, 12, 24 weeks of treatment | Pre-dose and 4 hr-post dose of plasma concentrations |
| To evaluate the potential effect of each AF on PK of BBT-877 in patients with IPF | 0, 4, 12, 24 weeks of treatment | Pre-dose and 4 hr-post dose of plasma concentrations. |
| To assess the safety of BBT-877 compared to placebo | over 24 weeks | The investigator will be asked to provide an assessment of the severity of the AE using the following categories: Mild: Usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: Usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the patient. Severe: Interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. |
| To assess the change in IPF symptoms from the patient perspective after 24 weeks of treatment of BBT-877 compared to placebo | after 24 weeks of treatment | Change in overall IPF symptoms as measured by the L-IPF total score from baseline |
Countries
Australia, Israel, Poland, South Korea, United States
Outcome results
None listed